Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CuraGen (CRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Frank Perlmutter who wrote (23)	4/23/1998 10:02:00 PM
From: fut_trade	Read Replies (1) \| Respond to of 478

My guess is that what happened today is similar to what happened a week ago when Lehman Brothers initiated coverage of this stock with a venture outperform rating. The stock was moving upward near 12 1/2, and about ten minutes after Lehman brothers initiated coverage, the stock moved down very rapidly. I don't believe the ask ever dropped below 10 1/2 today, so I didn't bother to increase my position. After the stock dropped, it moved back up on good volume. As far as I know, the fundamentals of the stock are better since the IPO, and I'm not aware of any reason why someone should sell their position. As noted a couple of posts back, several insiders bought stock during the IPO. quote.yahoo.com

To: Frank Perlmutter who wrote (23)	5/20/1998 1:29:00 PM
From: fut_trade	Read Replies (1) \| Respond to of 478

Well Frank, my yahoo news isn't working, I can't read recent messages on the Yahoo! stock threads, and to top it off - I just lost my real time quotes to CBS MarketWatch RT. I think the damage has been done already, and hopefully several months from now things will be much better off. Buy on weakness, sell into strength - right? I keep telling myself book value is about $5.86, Soros is a big owner, and Pioneer HiBred just doubled funding to Curagen. The Biotech sector has been weak lately, and Curagen doesn't really have anything at this point - so there isn't much of a chance for bad news relating specifically to Curagen.